PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Buhmann, R. ; Simoes, B. ; Stanglmaier, M.* ; Yang, T. ; Faltin, M.* ; Bund, D. ; Lindhofer, H.* ; Kolb, H.-J.

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion.

Bone Marrow Transplant. 43, 383-397 (2009)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL). Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases. Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 mu g) followed by DLI or SCT. Thereby, all CLL patients showed a prompt but transient clinical and hematological response. In one patient with HG-NHL, we observed a halt in progression for almost 4 months. Side effects (fever, chills and bone pain) were tolerable and appeared at antibody dose levels between 40 and 200 mu g. The cytokine pro. le was characterized by transient increases of IL-6, IL-8 and IL-10. Neither human anti-mouse antibodies nor GVHD developed, allowing repeated treatment courses. In summary, the trifunctional antibody Bi20 induced prompt antitumor responses in extensively pretreated, p53-mutated alemtuzumab and rituximab refractory patients indicating its therapeutic potential.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.998
1.240
41
43
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Adoptive immunotherapy; Donor lymphocyte infusion; Allogeneic transplantation; B-cell malignancies; Bispecific antibody; Versus-host-disease; Metastatic breast-cancer; Bispecific antibodies; Phase-i; Rituximab; Transplantation; Chemotherapy; Leukemia; Therapy; Blood
Sprache
Veröffentlichungsjahr 2009
HGF-Berichtsjahr 2010
ISSN (print) / ISBN 0268-3369
e-ISSN 1476-5365
Zeitschrift Bone Marrow Transplantation
Quellenangaben Band: 43, Heft: 5, Seiten: 383-397 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Begutachtungsstatus Peer reviewed
Institut(e) CCG Hematopoetic Cell Transplants (IMI-KHZ)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-520300-001
DOI 10.1038/bmt.2008.323
WOS ID WOS:000264088400006
Scopus ID 62549086034
PubMed ID 18850012
Erfassungsdatum 2009-12-31
[➜Korrektur melden]